Difficulty: Medium
Average Score: 74%
Practice
Pregnant women who are HIV positive:
Correct answer
B
Rationale
Pregnant HIV-positive women are treated with combination antiretroviral therapy (ART) to prevent mother-to-child transmission (MTCT) and maintain maternal health. Modern regimens (e.g., tenofovir/emtricitabine/dolutegravir) suppress viral loads to undetectable levels, reducing MTCT risk from 25-45% to <1%, per WHO and NIH guidelines. Option A, AZT (zidovudine) alone, is obsolete used in the 1990s (ACTG 076), it's less effective than combinations and doesn't address resistance prevention. Option C, avoiding ART due to teratogenicity, is outdated while efavirenz was once avoided, current drugs like dolutegravir are safe (Tsepamo study), balancing efficacy and fetal safety. Option D, 'high resistance risk,' isn't pregnancy-specific resistance stems from non-adherence, not gestation. Combination ART, supported by decades of data, ensures viral suppression across pregnancy stages, making B the standard of care and evidence-based choice.